Physician profile
Charles A Atkinson
NPI 1871593731
$5,428.87
in general payments reported to CMS, 2019-2025
12 companies · $347 in 2025
The $347 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.68 · 2020: $241 · 2021: $97.79 · 2022: $81.74 · 2023: $4,408 · 2024: $164 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,170 · Food and Beverage: $749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,170.00 |
| Food and Beverage | $749.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $4,784.79 | 2021-2025 | Integra, Omnigraft, Integra Dermal Regeneration Template |
| Ethicon US, LLC | $215.14 | 2019-2023 | Stratafix |
| Covidien LP | $145.42 | 2020 | |
| Intuitive Surgical, INC. | $71.11 | 2023 | Da Vinci Surgical System |
| Medtronic, INC. | $52.56 | 2022-2024 | Absorbatack |
| Boston Scientific Corporation | $33.99 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.65 | 2021 | |
| Abbvie INC. | $24.85 | 2024 | |
| Surgenex LLC | $21.16 | 2025 | Surgraft, Surmatrix, Pellograft |
| Tactile Systems Technology INC | $18.28 | 2021 | |
| Allergan, INC. | $17.21 | 2022 | |
| Smith+Nephew, INC. | $16.71 | 2024 | Collagenase Santyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Atkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.